Medical device firm Retractable's Q3 sales dip

Reuters

Nov 15

Medical device firm Retractable's Q3 sales dip

Overview

Retractable Technologies Q3 2025 sales slightly declined to $10.1 mln from $10.3 mln last year
Operating loss for Q3 2025 reduced to $3.7 mln from $5.1 mln last year
Company reports Q3 net income of $371 thousand, aided by $2.4 mln unrealized gains

Outlook

Tariffs expected to continue impacting costs in future periods
Uncertainty remains regarding timing of future international orders

Result Drivers

TARIFF IMPACT - Co says tariffs continue to materially affect costs, spending $2.3 mln on tariffs in first nine months of 2025
PRODUCT MIX - Higher domestic selling prices due to shift in product mix, with decreased EasyPoint needle sales
INTERNATIONAL SALES - International revenues increased 25% in Q3, but average selling price declined due to product discounts

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Sales		$10.10 mln
Q3 Operating Income		-$3.70 mln

Press Release: ID:nBw2MxtN9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583897236"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583897236\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583897236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 04:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583897236","market":"nz","top_or_hot":-1,"title":"Medical device firm Retractable's Q3 sales dip","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Medical device firm Retractable's Q3 sales dip</title></head><body><p><span>Overview</span></p><ul><li><p>Retractable Technologies Q3 2025 sales slightly declined to $10.1 mln from $10.3 mln last year</p></li><li><p>Operating loss for Q3 2025 reduced to $3.7 mln from $5.1 mln last year</p></li><li><p>Company reports Q3 net income of $371 thousand, aided by $2.4 mln unrealized gains</p></li></ul><p><span>Outlook</span></p><ul><li><p>Tariffs expected to continue impacting costs in future periods</p></li><li><p>Uncertainty remains regarding timing of future international orders</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>TARIFF IMPACT - Co says tariffs continue to materially affect costs, spending $2.3 mln on tariffs in first nine months of 2025</p></li><li><p>PRODUCT MIX - Higher domestic selling prices due to shift in product mix, with decreased EasyPoint needle sales</p></li><li><p>INTERNATIONAL SALES - International revenues increased 25% in Q3, but average selling price declined due to product discounts</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Sales</p></td><td></td><td><p>$10.10 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$3.70 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw2MxtN9a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medical device firm Retractable's Q3 sales dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedical device firm Retractable's Q3 sales dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-15 04:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Medical device firm Retractable's Q3 sales dip</title></head><body><p><span>Overview</span></p><ul><li><p>Retractable Technologies Q3 2025 sales slightly declined to $10.1 mln from $10.3 mln last year</p></li><li><p>Operating loss for Q3 2025 reduced to $3.7 mln from $5.1 mln last year</p></li><li><p>Company reports Q3 net income of $371 thousand, aided by $2.4 mln unrealized gains</p></li></ul><p><span>Outlook</span></p><ul><li><p>Tariffs expected to continue impacting costs in future periods</p></li><li><p>Uncertainty remains regarding timing of future international orders</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>TARIFF IMPACT - Co says tariffs continue to materially affect costs, spending $2.3 mln on tariffs in first nine months of 2025</p></li><li><p>PRODUCT MIX - Higher domestic selling prices due to shift in product mix, with decreased EasyPoint needle sales</p></li><li><p>INTERNATIONAL SALES - International revenues increased 25% in Q3, but average selling price declined due to product discounts</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Sales</p></td><td></td><td><p>$10.10 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$3.70 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw2MxtN9a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ11Q:1","article_id":"2583897236","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583897236","pubTimestamp":1763151751,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medical device firm Retractable's Q3 sales dipOverviewRetractable Technologies Q3 2025 sales slightly declined to $10.1 mln from $10.3 mln last yearOperating loss for Q3 2025 reduced to $3.7 mln from ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","RVP":"Retractable Technologies Inc"},"translate_title":"医疗器械公司Retractable第三季度销售额下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVP":0.9},"content_text":"Medical device firm Retractable's Q3 sales dipOverviewRetractable Technologies Q3 2025 sales slightly declined to $10.1 mln from $10.3 mln last yearOperating loss for Q3 2025 reduced to $3.7 mln from $5.1 mln last yearCompany reports Q3 net income of $371 thousand, aided by $2.4 mln unrealized gainsOutlookTariffs expected to continue impacting costs in future periodsUncertainty remains regarding timing of future international ordersResult DriversTARIFF IMPACT - Co says tariffs continue to materially affect costs, spending $2.3 mln on tariffs in first nine months of 2025PRODUCT MIX - Higher domestic selling prices due to shift in product mix, with decreased EasyPoint needle salesINTERNATIONAL SALES - International revenues increased 25% in Q3, but average selling price declined due to product discountsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Sales$10.10 mlnQ3 Operating Income-$3.70 mlnPress Release: ID:nBw2MxtN9aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}